跳至主要内容
临床试验/NCT05714774
NCT05714774招募中不适用

Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer Treatment Feasibility Study

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年3月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
2
主要终点
The percentage of analyses that could be completed for each of the three HIFU necrosis detection techniques

研究概览

简要总结

The ELASTO-US study is a single center feasibility study to evaluate 3 methods of analyzing real-time ultrasound images acquired during High Intensity Focused Ultrasound (HIFU) treatment in patients with localized prostate cancer.

Real-time ultrasound acquisitions will be programmed at specific times and recorded during HIFU treatment. At the end of the treatment, these recordings will be exported in an anonymized way and analyzed according to the 3 different methods.

A multiparametric-MRI will be performed in addition to the usual practice within 5 days after the treatment in order to control the area necroticised by the treatment. The mp-MRI will be the reference method against which the results obtained by the 3 methods of ultrasound image analysis will be compared.

Techniques capable of providing safe and robust information on the progress of HIFU-generated necrosis would greatly limit the risks of overtreatment that can lead to side effects such as urinary incontinence as well as the risks of under treatment that can lead to cancer recurrence.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patient who has been clearly informed of the study and has agreed, with sufficient time for reflection, to participate by signing the study informed consent form.
  • Male aged ≥ 50 years,
  • PSA ≤ 15 ng/mL
  • diagnosis of localized prostate cancer (stage T1 or T2) with a Gleason score of ≤ 7
  • Focal, hemiablation or ablation HIFU treatment validated in Multidisciplinary Concerted Meeting
  • Patient enrolled in Medicare or equivalent plan.
  • Interpretable preoperative multiparametric MRI performed within 180 days prior to surgery

排除标准

  • an ASA score >3
  • brachytherapy for prostate cancer
  • Person of full age protected by law (person under guardianship or curatorship).
  • Contraindication to HIFU treatment as defined in the Focal One instructions for use : - Multiple intraprostatic calcifications inducing, on ultrasound, a shadow cone in the prostate preventing the penetration of ultrasound and therefore the realization of the treatment.
  • Presence of permanent radioactive implants in the rectal wall.
  • Presence of an implant (stent, catheter) located less than 1 cm from the treatment area.
  • Fistula of the urinary tract or rectum.
  • Anal or rectal fibrosis, anal or rectal stenosis or other abnormalities making insertion of the Focal One® catheter difficult.
  • Anatomical abnormality of the rectum or rectal mucosa.
  • Patient with an artificial sphincter, penile prosthesis or intraprostatic implant, such as a stent.
  • History of inflammatory bowel disease.
  • Current urogenital infection (infection should be treated prior to HIFU treatment).
  • Patient allergic to latex with known severe reactionsCounter-indications to anesthesia

研究组 & 干预措施

Patients with localized prostate cancer

Experimental

Patients with localized prostate cancer for which focal treatment, hemi-ablation or total ablation of the prostate is indicated will be treated by HIFU applied by FocalOne device.

干预措施: HIFU treatment of prostate cancer (Device)

结局指标

主要结局

The percentage of analyses that could be completed for each of the three HIFU necrosis detection techniques

时间窗: At day 0

To determine the feasibility of implementing the Gray Level Histogram, The Nakagami imaging and proposed in this study, different factors will take into account : the quality of the acquired ultrasound images, the quality of the ultrasound image registration and the quality of the MRI image registration. The implementation of passive elastography, one of the three new methods proposed in this study, requires the presence of a sufficient wavefield in the tissue under study. An ultrasound expert will evaluate this aspect and determine whether or not the mechanical properties of the tissue can be assessed by passive elastography.

次要结局

  • To assess of the impact of patient characteristics and treatment history for prostate cancer.(at the latest on day 5 after HIFU treatment)
  • To compare the segmentation of the necrotic zone obtained with the studied parameter to the segmentation obtained with the post treatment MRI(at the latest on day 5 after HIFU treatment)
  • To compare the segmentation of the partially necrotic zone obtained with the studied parameter to the segmentation obtained with the post treatment MRI.(at the latest on day 5 after HIFU treatment)
  • To determinate the threshold to differenciate the partially necrotic area from the non necrotic area(at the latest on day 5 after HIFU treatment)
  • To determinate the threshold to differenciate the necrotic area from the non necrotic area(at the latest on day 5 after HIFU treatment)
  • To assess of the tolerance(at the latest on day 5 after HIFU treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验